Safety and Efficacy of a Head Lice Shampoo

Oystershell

Status

Completed

Conditions

Head Lice

Treatments

Drug: Pyrethrum Extract

Device: Silcap Shampoo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06333054

NCLIN0091/ 14ct/mp37li

Details and patient eligibility

About

This study is designed to compare the effectiveness and safety of test head lice shampoo (Test product) versus Goldgeist® Forte (reference product) following two applications.

Full description

The primary objective was to show, that the cure rate after local application of Test head lice shampoo is better than a predefined limit. It had to be shown, that the Test head lice shampoo achieved a cure rate superior to 70% (cure rate at the end of day 10, corrected for re-infestation).

Enrollment

109 patients

Sex

All

Ages

1+ year old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Gender: male/female
Age: ≥ 1 year of age at the time of signing the informed consent
Patients with active head lice infestation of at least 5 living lice and 5 apparently living eggs
Patient or his/her guardian must be capable of understanding and providing written informed consent
The patient or his/her legal representative must give written informed consent, after having been oral and written informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the subjects participating in the study
Patients must agree to not use any other ant-lice treatment for the duration of the study
Female patients:

are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent duringthe study. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom with contraceptive gel

or are women of non-childbearing potential, defined as: women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation),
or women who are ≥ 60 years of age.

Exclusion criteria

Known allergic reactions or hypersensitivity to the active ingredients used or the constituents
Patients with known skin allergies, multiple drug allergies or multiple allergies to cosmetic products
Pregnant or breast feeding women
Patient underwent treatment with any form of head lice treatment within the last 30 days prior to the Screening Visit (day 0)
Patients with chronic scalp disorder
Individuals on systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results
Subjects with hair longer than mid-back
Patients suspected or known not to follow instructions
Patients or his/her legal representative who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
Previous participation in this study or participation in any other investigational trial within the preceding 30 days
The patients are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
The patients are Oystershell employees or are employees of third-party organizations involved in the study.